285 related articles for article (PubMed ID: 30489631)
1. Uterine cancer in Jewish Israeli BRCA1/2 mutation carriers.
Laitman Y; Michaelson-Cohen R; Levi E; Chen-Shtoyerman R; Reish O; Josefsberg Ben-Yehoshua S; Bernstein-Molho R; Keinan-Boker L; Rosengarten O; Silverman BG; Perri T; Korach J; Mor P; Ephrat Ben-Baruch N; Levy Lahad E; Friedman E;
Cancer; 2019 Mar; 125(5):698-703. PubMed ID: 30489631
[TBL] [Abstract][Full Text] [Related]
2. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
[TBL] [Abstract][Full Text] [Related]
3. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A
Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239
[TBL] [Abstract][Full Text] [Related]
4. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations.
Shu CA; Pike MC; Jotwani AR; Friebel TM; Soslow RA; Levine DA; Nathanson KL; Konner JA; Arnold AG; Bogomolniy F; Dao F; Olvera N; Bancroft EK; Goldfrank DJ; Stadler ZK; Robson ME; Brown CL; Leitao MM; Abu-Rustum NR; Aghajanian CA; Blum JL; Neuhausen SL; Garber JE; Daly MB; Isaacs C; Eeles RA; Ganz PA; Barakat RR; Offit K; Domchek SM; Rebbeck TR; Kauff ND
JAMA Oncol; 2016 Nov; 2(11):1434-1440. PubMed ID: 27367496
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract][Full Text] [Related]
6. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
7. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
[TBL] [Abstract][Full Text] [Related]
8. Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA;
Eur J Cancer; 2017 Oct; 84():114-120. PubMed ID: 28802188
[TBL] [Abstract][Full Text] [Related]
9. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
[TBL] [Abstract][Full Text] [Related]
10. BRCA germline mutations in women with uterine serous carcinoma--still a debate.
Lavie O; Ben-Arie A; Segev Y; Faro J; Barak F; Haya N; Auslender R; Gemer O
Int J Gynecol Cancer; 2010 Dec; 20(9):1531-4. PubMed ID: 21119368
[TBL] [Abstract][Full Text] [Related]
11. Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline
Lim H; Kim SI; Hyun S; Lee GB; Seol A; Lee M
Yonsei Med J; 2021 Dec; 62(12):1090-1097. PubMed ID: 34816639
[TBL] [Abstract][Full Text] [Related]
12. The yield of full BRCA1/2 genotyping in Israeli high-risk breast/ovarian cancer patients who do not carry the predominant mutations.
Barnes-Kedar I; Bernstein-Molho R; Ginzach N; Hartmajer S; Shapira T; Magal N; Kalis ML; Peretz T; Shohat M; Basel-Salmon L; Friedman E; Bazak L; Goldberg Y
Breast Cancer Res Treat; 2018 Nov; 172(1):151-157. PubMed ID: 30014164
[TBL] [Abstract][Full Text] [Related]
13. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
14. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
15. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
[TBL] [Abstract][Full Text] [Related]
16. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers.
Reitsma W; Mourits MJ; de Bock GH; Hollema H
Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
Casey MJ; Bewtra C
Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
[TBL] [Abstract][Full Text] [Related]
18. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
19. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers.
Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J
Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
